Chau Nguyen, MD
Internal Medicine · Lakeland, FLNPI 1467424564
Payments from drug & device makers
Across 612 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Pfizer$1K
- AstraZeneca$1K
- Amgen$985
- Boehringer Ingelheim$764
- plus $4K from 30 others
What the payments were for
- Food & beverage$10,509100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 66 | $1,255 |
| Lilly USA, LLC | 67 | $1,089 |
| Pfizer | 59 | $1,053 |
| AstraZeneca | 66 | $1,051 |
| Amgen | 70 | $985 |
| Boehringer Ingelheim | 43 | $764 |
| AbbVie(2 entities) | 32 | $609 |
| GSK | 30 | $506 |
| Novartis | 30 | $478 |
| Merck | 21 | $330 |
| Dexcom, Inc. | 16 | $319 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $297 |
| Sanofi-aventis U.S. LLC | 14 | $226 |
| Exact Sciences | 9 | $212 |
| Johnson & Johnson | 14 | $207 |
| Phathom Pharmaceuticals, Inc. | 8 | $176 |
| Bayer | 6 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $103 |
| Teva Pharmaceuticals USA, Inc. | 4 | $102 |
| Axsome Therapeutics, Inc. | 4 | $98 |
| Esperion Therapeutics, Inc. | 5 | $91 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $78 |
| Kowa Pharmaceuticals America, Inc. | 4 | $58 |
| Sunovion Pharmaceuticals Inc. | 3 | $56 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| Astellas Pharma US Inc | 2 | $35 |
| Amneal Pharmaceuticals LLC | 2 | $30 |
| Mylan Specialty L.p. | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Corcept Therapeutics | 1 | $22 |
| Abbott | 1 | $18 |
| Medtronic | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $11 |
How this compares
$10,530 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 299 | $286,572 |
| MounjaroTirzepatide | 121 | $147,644 |
| OzempicSemaglutide | 106 | $117,828 |
| RybelsusSemaglutide | 59 | $90,553 |
| XareltoRivaroxaban | 90 | $88,371 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $52,084 |
| JardianceEmpagliflozin | 46 | $39,252 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $37,977 |
| JanuviaSitagliptin Phosphate | 20 | $26,593 |
| Budesonide ErBudesonide | 12 | $25,700 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $23,654 |
| CreonLipase/Protease/Amylase | 11 | $21,575 |
| TrulicityDulaglutide | 21 | $18,552 |
| Advair HfaFluticasone Propion/Salmeterol | 46 | $16,447 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $16,108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,053 | $286,572299 claims |
| Novo NordiskOzempic, Rybelsus | $1,255 | $208,381165 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,089 | $166,196142 claims |
| Johnson & JohnsonXarelto | $207 | $88,37190 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy, Shingrix | $506 | $67,563130 claims |
| Boehringer IngelheimJardiance | $764 | $39,25246 claims |
| MerckJanuvia | $330 | $26,59320 claims |
| AbbVieCreon, Synthroid | $609 | $26,53769 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $30 | $6,055684 claims |
| AstraZenecaSymbicort | $1,051 | $4,97917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Lakeland
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.